Loading...
•
Mar 31, 2024
Novavax Q1 2024 Earnings Report
Announced first quarter financial results and operational highlights.
Key Takeaways
Novavax announced its Q1 2024 financial results, highlighting a co-exclusive licensing agreement with Sanofi and progress on its COVID-19 vaccine and CIC program.
Entered into a co-exclusive licensing agreement with Sanofi.
Continued to advance its COVID-19 vaccine for the upcoming 2024-2025 vaccination season.
Planned for the launch of Phase 3 CIC and standalone influenza program in the second half of this year.
Focused on reducing operating expenses.
Novavax
Novavax
Novavax Revenue by Segment
Novavax Revenue by Geographic Location
Revenue by Segment
Product sales Revenue
CapyFin.comLicensing, royalties, and other Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comEurope Revenue
CapyFin.comRest of the world Revenue
CapyFin.com Forward Guidance
Novavax is updating its Full Year 2024 Financial Guidance and expects to achieve the following objectives: Total potential contract value for APAs outstanding, as of March 31, 2024, was over $600 million related to expected dose deliveries for the second quarter of 2024 through 2026. Novavax is prepared to initiate an additional cost reduction program to reduce 2025 R&D plus SG&A expenses to below $500 million.
Positive Outlook
- Total potential contract value for APAs outstanding, as of March 31, 2024, was over $600 million related to expected dose deliveries for the second quarter of 2024 through 2026.
- Prepared to initiate an additional cost reduction program to reduce 2025 R&D plus SG&A expenses to below $500 million.
- Focus on creating value from R&D and business development.
- Deliver on existing Novavax APAs.
- Prioritize enabling Sanofi to successfully execute its commercial and development plans under the agreement.
Revenue & Expenses
Visualization of income flow from segment revenue to net income